Specialized care for hepatocellular carcinoma (HCC) and cholangiocarcinoma with advanced systemic therapy, loco-regional treatments, and multidisciplinary management.
Expert management of hepatocellular carcinoma (HCC) and cholangiocarcinoma with cutting-edge systemic therapies, loco-regional treatments, and comprehensive multidisciplinary care. We specialize in TACE, RFA, and novel targeted therapies.
Multiphase CT, MRI with contrast, and PET-CT for accurate staging and treatment planning.
AFP, CEA, CA19-9, and molecular profiling for personalized treatment selection.
Child-Pugh and MELD scoring to determine treatment eligibility and prognosis.
Right upper quadrant pain/fullness, abdominal swelling, early satiety.
Yellowing of eyes/skin, dark urine, pale stools, pruritus due to cholestasis.
Unintentional weight loss, fatigue, loss of appetite, fever in some cases.
Chronic Hepatitis B or C infection significantly increases HCC risk.
Cirrhosis from alcohol, NAFLD/NASH, hemochromatosis, aflatoxin exposure.
Metabolic syndrome, diabetes, hereditary conditions (e.g., Wilson disease).
Regular imaging studies and biomarker monitoring to assess treatment response and disease progression.
Collaboration with hepatobiliary surgery, interventional radiology, and hepatology for comprehensive care.
Managing treatment side effects, liver function, and maintaining quality of life throughout treatment.